Short answer
Nuvectis Pharma, Inc. (NVCT) filed an 8-K current report with the SEC on August 21, 2026 reporting Item 8.01 (Other Events). New ATM program enables Nuvectis to sell common shares opportunistically through Jefferies.
Nuvectis Pharma, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- New ATM program enables Nuvectis to sell common shares opportunistically through Jefferies
- $200 million shelf registration expands potential financing capacity across securities
- Jefferies compensation up to 3.0% of gross ATM proceeds, reducing net capital raised
- Actual proceeds and dilution depend on shares sold and offering prices
- Prior ATM terminated July 20, 2026, ending sales under its February 2026 prospectus supplement
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Nuvectis Pharma, Inc. 8-K filings
Get the next NVCT 8-K as it lands
Follow NVCT for push alerts, or ask the research agent what this filing means.